Zilico Ltd., a medical device manufacturer based in Britain, will present a new type of diagnostic tool for cancer at Medica 2012. The company’s new product is due for release in 2013.
According to statements from the company, the new diagnostic tool provides real-time, high-accuracy and high-speed detection of cervical dysplasia. Traditional detection technologies for this type of cancer may have lag times of up to several weeks. The handheld device comes with a docking station and a disposable sleeve. With the use of electrical impedance spectroscopy technology, Zilico’s new diagnostic tool can measure the electrical resistivity of individual cells. Since the conductive properties of cancerous, pre-cancerous and noncancerous cells are different, electrical resistivity can provide non-invasive detection of tumors.
In a prepared statement, CEO Sameer Kothari said, “The diagnostic tool, including the recent pivotal trial data, has the potential to make a significant impact on how women are managed within the cervical cancer pathway. This makes the Zilico proposition very attractive to those considering potential partnerships and we look forward to meeting interested parties at Medica.”